| Public Notice | Monitoring | N/A | N/A | Feb 18, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 18, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 18, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 18, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 8, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 8, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 8, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 8, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Nov 19, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Nov 19, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 9, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 9, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 9, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 9, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 9, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 9, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 9, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 9, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 3, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 3, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | May 24, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | May 24, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | May 24, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | May 24, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 24, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 24, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 24, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 24, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 4, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 4, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 4, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 4, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 4, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | May 4, 2024 | Resolved | N/A |
| E. COLI | Monitoring | 0 | N/A | Apr 11, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Apr 11, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Apr 11, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Apr 11, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| Lead and Copper Rule | Monitoring | N/A | N/A | Mar 29, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Mar 29, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 20, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 20, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 20, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 20, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 20, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Mar 20, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Mar 20, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Mar 20, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Mar 20, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Mar 20, 2024 | Resolved | N/A |
| E. COLI | Monitoring | 0 | N/A | Feb 9, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Feb 9, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Feb 9, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Feb 9, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 8, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 8, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 8, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 8, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0105 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0105 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0105 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0105 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Dec 19, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 19, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 19, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 19, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Nov 22, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Nov 22, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Nov 13, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Nov 13, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Nov 13, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Nov 13, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 13, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 13, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 13, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 13, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 7, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 7, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 7, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 7, 2023 | Resolved | N/A |
| Lead and Copper Rule | Health-Based | N/A | N/A | Oct 21, 2023 | Active | N/A |
| Lead and Copper Rule | Health-Based | N/A | N/A | Oct 21, 2023 | Active | N/A |
| Lead and Copper Rule | Health-Based | N/A | N/A | Oct 21, 2023 | Active | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| E. COLI | Monitoring | 0 | N/A | Sep 27, 2023 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Sep 27, 2023 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Sep 27, 2023 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Sep 27, 2023 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 13, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 13, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 13, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 13, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 8, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 8, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 8, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 8, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 7, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 7, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 7, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 7, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 7, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 7, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 7, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 7, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 7, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 7, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 7, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 7, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 7, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 7, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 7, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 7, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 29, 2021 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Chlorine | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Mar 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Mar 30, 2021 | Resolved | N/A |